NUCLEOLIN and breast cancer: A similar pattern was observed in SKBR3 breast cancer cells, which endogenously express high levels of ErbB2: here, introduction of siRNA targeted against ErbB2 has significantly reduced ErbB2-nucleolin interaction, compared to untreated cells or cells treated with a non-specific control siRNA (Figure 1B).